Monday , 2 October 2023

Description Of Diseases Seelos Therapeutics Is Focused On

Acute Suicidal Ideation and Behavior (ASIB)

  • 12.2 million adults in the U.S. (~700,000 worldwide) had serious thoughts of committing suicide in 2021 of which
    • 3.2 million made suicide plans,
    • 1.2 million attempted suicide and
    • 47,646 were successful which was up almost 4% in 2021 making it the 10th leading cause of death.
    • Source.
  • In addition, Depression currently affects 264 million people globally and 20% of Americans ages 18+ in any given year
  • Current treatments for ASIB include hospitalization and/or anti-depressants – many with a black box warning as they can lead to increase in suicidal thoughts in certain populations.

 Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig’s Disease

  • is a fatal (life expectancy of 10 to 20 years) neurodegenerative disease characterized by progressive muscle paralysis determined by the degeneration of neurons in the motor cortex brainstem and spinal cord,
  • has Orphan designation in the U.S. and the European Union,
  • has shown in in-vivo studies that treatment with oral trehalose:
    • delayed the progression of the disease thereby prolonging survival,
    • reduced skeletal muscle denervation,
    • reduced motor neuron loss and skeletal denervation,
    • improved autophagy flux and
    • decreased aggregation of SOD1 and SQSTM1/p62.

Spinocerebellar Ataxia (SCA)

  • is a serious adult-onset (begins between the ages of 20 and 50) neurodegenerative disease caused by degeneration of the cerebellum characterized by:
    • progressive unsteadiness of gait and stance,
    • impaired coordination of limb movements,
    • slurred speech and
    • abnormal eye movements
  • commonly affects individuals of Portuguese/Azorean descent,
  • has Orphan designation in the U.S. and the European Union and
  • has Fast Track designation in the U.S.

SCA type 3, also known as Machado-Joseph Disease (MJD):

  • is a progressive cerebellar ataxia and is known to cause progressively severe disability and often premature death.
    • Weekly infusions of SLS-005 were found to be generally safe and tolerated with no changes in safety
      parameters required.
    • Patients remained stable during treatment with no significant change in SARA score over 6 months and the 6 patients who continued to receive treatment for 12 months had SARA scores that remained stable.
    • Trehalose improved symptoms in 61.5% of SCA patients